Please assess the completion status of the following clinical trial:

Trial Title: Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed inform consent prior to any study-mandated procedures~2. Adult patients 18-80 years of age~3. World Health Organization Group 1 PAH associated with scleroderma (SSc-PAH)~4. WHO functional Class II-III~5. 6MWD 150 to 450 meters~6. Right heart catheterization demonstrating mPAP≥ 25 mmHg and PCWP or left ventricular end diastolic pressure ≤15mm Hg and pulmonary vascular resistance ≥240 dynes/cm-5 (3 Wood units) within 12 weeks prior to study entry.~7. ACR defined systemic sclerosis~Exclusion Criteria:~1. Pulmonary hypertension associated with~   * PAH of any etiology other than scleroderma~  * PH of any etiology other than WHO Group I PAH~  * Pulmonary venous hypertension defined as PCWP or LVEDP \>15 mHg~  * Untreated sleep apnea with AHI \>20 or SaO2 Nadir \<87%~  * Chronic thromboembolic disease~  * Sarcoidosis~2. Participation in a clinical investigational study within the previous 30 days~3. Moderate to severe hepatic impairment (e.g., Child-Pugh Class B or C)~4. Renal failure defined as:~   * estimated creatinine clearance \<30 m/min~  * serum creatinine\>2.5 mg/dl~5. Serum aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) \> 1.5 times the upper limit of normal~6. Systolic blood pressure \< 90mmHg~7. Recently started (\< 8 weeks prior to randomization) or planned cardiopulmonary rehabilitation program based on exercise~8. Pregnant or lactating women~9. Need for HAART therapy~10. Planned treatment or treatment with another investigational drug within 1 month prior to start~11. Moderate to severe interstitial lung disease, defined by FVC \< 80% or evidence on HRCT of fibrosis or ground glass changes involving more than 30% of lung parenchyma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dimethyl Fumarate (DMF) (Type: ACTIVE_COMPARATOR): Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Twice daily oral doses of placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).